Pharmaceutical Industry News Roundup: April 2020

by Staff Writer

Each month, MMS shares key stories on the evolution of the pharmaceutical industry. Here is a selection from April:

Global leaders unite to ensure everyone everywhere can access new vaccines, tests and treatments for COVID-19World Health Organization (WHO)

Currently, the COVID-19 pandemic has affected more than 2.4 million people worldwide. To address this issue, heads of state and global health leaders recently made a commitment to work collaboratively to accelerate the development of new treatments for COVID-19.

Read the full news release 

Whitepaper: six changes that pharmaceutical companies should consider in response to COVID-19MMS

In the wake of the pandemic of COVID-19, regulators, health authorities, and lawmakers across the globe have rushed to implement countermeasures and developed best practices to curtail the spread. Experts at MMS have reviewed these guidances and have recommended six changes that pharmaceutical companies should consider in response to COVID-19.

Access the whitepaper here

COVID-19 vaccine trackerRegulatory Focus

Regulatory Focus has put together a tracker for COVID-19 vaccine development. The tracker lists major vaccine candidates in development for COVID-19 prevention.

Jeff Craven has the full story

CDISC releases data management guidance for COVID-19 trials—CenterWatch

The Clinical Data Interchange Standards Consortium (CDISC) has released a case report form template to help sites apply the organization’s standards to data anomalies resulting from COVID-19 trial adjustments. The guide also helps users handle protocol deviations and other disruptions caused by the pandemic.

Read the story via CenterWatch

TrialAssure offers academics free reporting toolOutsourcing Pharma

TrialAssure announced that it will offer academic institutions free access to TrialAssure REGISTRY—the premiere clinical trial disclosure reporting application. Academic institutions can sign up for a TrialAssure subscription specific to this program—at no cost— allowing users free access for up to two years.

Read the article by Jenni Spinner

Former Gilead Sciences Head of Clinical Trial Disclosure and Data Transparency joins MMS and TrialAssure as Director of Global Transparency Strategy and Compliance MMS

Vaillant will lead the transparency and compliance efforts across MMS and TrialAssure global operations. TrialAssure is the technology arm of MMS and a leading, global software company focused on advancing clinical trial transparency. Bringing more than 20 years of clinical development experience, Vaillant has led various functions across clinical development at Gilead Sciences, Ambit Biosciences, Novartis, Amgen, and Pharmacia.

Stay up to date with all MMS news here

< Back to MMS Blog